- Home
- BIIB vs FER Comparison
BIIB vs FER Comparison
Compare BIIB & FER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- FER
- Stock Information
- Founded
- BIIB 1978
- FER 1952
- Country
- BIIB United States
- FER Netherlands
- Employees
- BIIB N/A
- FER N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- FER
- Sector
- BIIB Health Care
- FER
- Exchange
- BIIB Nasdaq
- FER NYSE
- Market Cap
- BIIB 18.8B
- FER 37.4B
- IPO Year
- BIIB 1991
- FER N/A
- Fundamental
- Price
- BIIB $127.50
- FER $52.00
- Analyst Decision
- BIIB Buy
- FER
- Analyst Count
- BIIB 27
- FER 0
- Target Price
- BIIB $188.17
- FER N/A
- AVG Volume (30 Days)
- BIIB 1.2M
- FER 148.5K
- Earning Date
- BIIB 07-31-2025
- FER 01-01-0001
- Dividend Yield
- BIIB N/A
- FER 1.71%
- EPS Growth
- BIIB 26.39
- FER 618.58
- EPS
- BIIB 10.12
- FER 4.63
- Revenue
- BIIB $9,816,400,000.00
- FER $9,469,924,426.00
- Revenue This Year
- BIIB N/A
- FER $4.96
- Revenue Next Year
- BIIB N/A
- FER $3.81
- P/E Ratio
- BIIB $12.69
- FER $11.22
- Revenue Growth
- BIIB 1.59
- FER 7.43
- 52 Week Low
- BIIB $110.04
- FER $37.93
- 52 Week High
- BIIB $236.48
- FER $56.43
- Technical
- Relative Strength Index (RSI)
- BIIB 45.02
- FER N/A
- Support Level
- BIIB $132.37
- FER N/A
- Resistance Level
- BIIB $137.84
- FER N/A
- Average True Range (ATR)
- BIIB 4.12
- FER 0.00
- MACD
- BIIB 0.01
- FER 0.00
- Stochastic Oscillator
- BIIB 25.82
- FER 0.00
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About FER FERROVIAL SE
Ferrovial SE is a Spanish industrial company. The company organizes itself into four segments: Toll Roads, Airports, Construction, and Energy. The Toll Roads segment develops and operates toll roads globally. The Airports segment includes the Development, financing and operation of airports. The Construction segment Designs and executes all public and private works, including most notably the construction of public infrastructures. The Energy segment focuses on innovative solutions for promoting, constructing and operating energy generation and transmission infrastructures.